Broncus Biotech Closes Series C of Multi-Tens Millions US Dollars
Broncus Biotech is a Hangzhou-based biotechnology with a focus on precision interventional therapy for lung diseases. The company recently announced the close of Series C fundraising of multi-tens million US dollars. The investment is led by Lake Bleu Capital, participated by Baidu Ventures, Qiming Ventures, Yinxin Investment, DH Capital and Jishi Capital.
The bankroll will help improve the core pipeline for diagnosis and treatment products, including research, clinical trials, registration and global market expansion.
Together with two other research-oriented companies – Broncus Medical, Inc. and Uptake Medical Technology, Inc., the startup focuses on developing precision minimally-invasive products. It has built a strategic partnership with Institutive Surgical and Olympus Europa in multiple areas.